To make money in Bio-Tech you need data, data come from clinical / hospital trials. Pre-Clinical trials, animals, are in full control of the scientists in their labs, just a few criteria to "obey". Clinical trials need regulator or hospital approvals, strictly regulated. To get those, pre- clinical data need to demonstrate exceptional safety and efficacy. That takes time and a thoroughly preparation. Any short coming at that stage will result in a knocked back approval for clinical trials by regulators, that would mean a 1 -2 year set back. Therefore, give them time, it is sooooo important to get that step right, otherwise good night.
The Paul Hopper companies ( IMU,CHM,RAD) are those who got it right every time first time by never ever rushing anything compromising essential requirements. So far IVX is doing exactly that, there is no alternative to it. If you cannot wait years, yes years, sell out immediately.
GLTA
IVX Price at posting:
1.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)